Search results
Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids and is considered to be the predominant antigen in APS and antibodies against B2GPI (anti-B2GPI) are recognised in the laboratory criteria for APS diagnosis.
- The role of beta-2-glycoprotein I in health and disease associating ...
Antibodies of the IgG or IgM isotype to β2GPI are one of the...
- The role of beta-2-glycoprotein I in health and disease associating ...
Vitamin K antagonists remain the mainstay of treatment for most patients with thrombotic antiphospholipid syndrome and, based on current data, appear superior to the more targeted direct oral anticoagulants. The potential role of immunomodulatory treatments in antiphospholipid syndrome management is receiving increased attention.
8 gru 2023 · In this review, we present 3 patients with aPL and/or APS who highlight treatment dilemmas, and we discuss background information that may help guide clinical judgment in developing individualized treatment plans for patients with these enigmatic antibodies.
Laboratory diagnosis of APLA depends upon the detection of a lupus anticoagulant, which prolongs phospholipid-dependent anticoagulation tests, and/or anticardiolipin (aCL) and anti-β 2 -glycoprotein-1 (β2GPI) antibodies. APLA are primarily directed towards phospholipid binding proteins.
Antibodies of the IgG or IgM isotype to β2GPI are one of the three criteria antibodies in APS diagnosis [4]; the others are the lupus anticoagulant (LA) assay and the anti-cardiolipin (aCL) assay. aCL from patients with APS (but not from non-APS patients) require β2GPI as a co-factor for CL-binding whilst the LA effect has been shown to be β2GPI...
3 wrz 2009 · In the most recent American College of Chest Physicians VTE treatment guidelines, 14 patients with VTE are broadly divided into 3 major categories for the purposes of treatment considerations: (a) those with cancer, (b) those in whom the VTE occurred in the setting of a reversible, provoking risk factor (ie, surgery, plaster cast immobilization ...
14 paź 2021 · Anti-β-2 glycoprotein I antibodies (anti-B2GPI) are often cited as the major pathogenically relevant antibody in antiphospholipid syndrome (APS), but it is unclear if there is clinical evidence to support this theory.
